A recent study reveals that the weight-loss medication semaglutide, marketed as Wegovy for obesity and Ozempic for diabetes, could potentially be produced for a mere $3 per month. This development stands to make the drug accessible to millions grappling with obesity and diabetes across 160 countries, particularly in lower-income regions where healthcare costs have been prohibitive.
The Global Obesity Crisis
As obesity rates surge worldwide, more than one billion individuals are currently living with this condition, with alarming increases observed in lower-income nations. Rapid shifts towards Western dietary patterns and increasingly sedentary lifestyles have exacerbated the issue. Last September, the World Health Organization (WHO) classified semaglutide as an essential medicine, yet the prohibitive costs of treatment have continued to hinder access for many.
Revolutionising Access to Treatment
New research, which has been shared in a pre-print format, suggests that mass production of semaglutide could be achieved for approximately $3 (around £2.35) per month for the injectable form. Alternative formulations, available as pills, might be produced for about $16 monthly. Dr Andrew Hill from the University of Liverpool, one of the study’s authors, emphasised the significance of these findings, stating, “These low prices open the door to worldwide access to an essential medicine.”
The researchers noted that key patents for semaglutide are set to expire this year in ten countries, including Brazil, China, India, South Africa, Turkey, Mexico, and Canada, commencing from 21 March. This expiration paves the way for generic alternatives to enter the market. Furthermore, an additional 150 nations have not filed patents for the drug, including many in Africa, potentially benefiting a vast population—69% of individuals with type 2 diabetes and 84% of those suffering from obesity.
A Call for Comprehensive Strategies
Prof François Venter from Witwatersrand University in Johannesburg highlighted the successful model of accessible treatments for conditions such as HIV, tuberculosis, malaria, and hepatitis in low- and middle-income countries. He argued that the same could be accomplished for semaglutide, provided that adequate policies and planning are implemented to ensure its responsible integration into healthcare systems.
Dr Nomathemba Chandiwana, chief scientific officer at South Africa’s Desmond Tutu Health Foundation, echoed these sentiments. She noted that cost has been a significant barrier to accessing essential medications in many African and developing countries. With approximately 27% of adults globally qualifying for semaglutide treatment, most reside in regions where access remains severely limited. The challenge now lies in how healthcare systems will incorporate these medications into broader strategies for tackling obesity and diabetes.
Addressing the Underlying Causes
While the prospect of affordable semaglutide offers hope, experts caution that simply providing treatments will not resolve the structural factors contributing to obesity. Issues such as food insecurity, poverty, urbanisation, and the proliferation of unhealthy food environments must be addressed alongside any medical interventions.
The implications of obesity extend far beyond weight itself, as it is linked to numerous health complications, including heart disease, diabetes, stroke, and certain cancers. Each year, excess weight contributes to an estimated 3.7 million deaths globally. The increase in diabetes cases—rising from 200 million in 1990 to 830 million by 2022—has been particularly pronounced in low- and middle-income countries, underscoring the urgent need for effective solutions.
The Path Forward
Semaglutide has been in use since its approval by US regulators in 2017, where it currently costs around $200 per month, and £120 in the UK. However, patents in much of Europe and the US still have five years before expiration, maintaining high prices in those markets.
This recent research aligns with earlier findings from Médecins Sans Frontières, which indicated that diabetes medications, including semaglutide, could be manufactured and distributed at significantly lower costs.
Why it Matters
The potential to produce semaglutide at a fraction of its current price could dramatically reshape access to vital healthcare for millions. By paving the way for generic competition and reducing financial barriers, this breakthrough holds the promise of significantly improving health outcomes in vulnerable populations. However, it is crucial to approach this advancement with a comprehensive strategy that addresses the underlying societal factors contributing to obesity and diabetes to ensure sustainable change in global health.
